Celgene Corp (CELG) 105.49 $CELG Celgene Corporation to

New Post Public Reply Private Reply Replies (0) Message Board

Sep 3, 2016 at 9:21 PM

Celgene Corp (CELG) 105.49 $CELG

Celgene Corporation to Webcast at Upcoming Investor Conferences and R&D Deep Dive in September
BusinessWire - Mon Aug 29, 6:30AM CDT
Celgene Corporation (NASDAQ:CELG) plans to present at two upcoming investor conferences and at an R&D deep dive in September where Celgene management will provide an overview of the Company. The conferences and R&D deep dive will be webcast live and the webcasts will be available in the Investor Relations section of the Company's website at www.celgene.com.
CELG: 105.49 (-0.88), CELGZ: 1.18 (+0.05)

Research Report on Biotech Equities -- Celgene, Sarepta Therapeutics, MannKind, and Opko Health
PR Newswire - Wed Aug 24, 6:35AM CDT
Stock-Callers.com has on its radar four Biotech stocks, namely: Celgene Corp. (NASDAQ: CELG), Sarepta Therapeutics Inc. (NASDAQ: SRPT), MannKind Corp. (NASDAQ: MNKD), and Opko Health Inc. (NASDAQ: OPK). According to Transparency Market Research, the global white biotechnology market will grow at a CAGR of 4.5% over the period between 2016 and 2024. White biotechnology, or industrial biotechnology, comprises all the biotechnology uses related to industrial processes. Learn more about these stocks by accessing their free research reports at:
OPK: 9.33 (+0.04), SRPT: 26.89 (+0.33), MNKD: 0.74 (unch), CELG: 105.49 (-0.88), CELGZ: 1.18 (+0.05)

Look for Shares of Celgene to Potentially Pullback after Yesterday's 1.71% Rise
Comtex SmarTrend(R) - Mon Aug 22, 12:22PM CDT
Celgene (NASDAQ:CELG) traded in a range yesterday that spanned from a low of $112.53 to a high of $114.47. Yesterday, the shares gained 1.7%, which took the trading range above the 3-day high of $112.95 on volume of 1.4 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
CELG: 105.49 (-0.88)

SmarTrend Watching for Potential Pullback in Shares of Celgene After 1.71% Gain
Comtex SmarTrend(R) - Mon Aug 22, 12:20PM CDT
Celgene (NASDAQ:CELG) traded in a range yesterday that spanned from a low of $112.53 to a high of $114.47. Yesterday, the shares gained 1.7%, which took the trading range above the 3-day high of $112.95 on volume of 1.4 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
CELG: 105.49 (-0.88)

ETFs in Focus on Pfizer's Medivation Acquisition
Zacks Equity Research - Zacks Investment Research - Mon Aug 22, 11:01AM CDT
The pharma giant, Pfizer (PFE) announced to acquire Medivation (MDVN) for $14 billion.
IHE: 147.95 (-0.83), MDVN: 80.85 (-0.08), GILD: 76.89 (-0.53), MRK: 62.98 (+0.08), PFE: 34.77 (+0.09), FHLC: 34.54 (+0.03), SNY: 39.18 (+0.77), VHT: 133.16 (+0.19), XLV: 72.65 (+0.08), CELG: 105.49 (-0.88)

Under Armour trade offers a 5% return in 32 days, or find similar option trades on Endo International, Sears Holdings, Celgene, and Barrick Gold Corporation
PR Newswire - Mon Aug 15, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for ABX, CELG, ENDP, SHLD, and UA.
UA: 38.56 (-1.19), ENDP: 19.82 (-0.41), ABX: 18.16 (+0.36), SHLD: 13.33 (-0.16), CELG: 105.49 (-0.88)

Dr. Jerome Zeldis, M.D., Ph.D., former Chief Medical Officer of Celgene, to Join Sorrento as Chief Medical Officer and President of Clinical Development
PR Newswire - Mon Aug 15, 8:00AM CDT
Sorrento Therapeutics, Inc. (NASDAQ: SRNE; "Sorrento"

, an antibody-centric, clinical-stage biopharmaceutical company developing new treatments for cancer, pain management, inflammation and autoimmune diseases, today announced that Dr. Jerome Zeldis, M.D., Ph.D., former Chief Medical Officer of Celgene Corporation (NASDAQ: CELG; "Celgene"

, has been appointed to the position of Chief Medical Officer and President of Clinical Development.
SRNE: 6.73 (-0.03), CELGZ: 1.18 (+0.05), CELG: 105.49 (-0.88)

Stock Market News for August 09, 2016
Zacks Equity Research - Zacks Investment Research - Tue Aug 09, 9:10AM CDT
Despite strong crude rally, major benchmarks closed in the red on Monday on the back of declines in healthcare stocks
PFE: 34.77 (+0.09), XOM: 87.42 (+0.58), AMGN: 169.77 (-0.36), PDCO: 46.89 (+0.86), COP: 40.92 (+0.32), BMY: 56.35 (-0.41), SLB: 78.55 (-0.41), CELG: 105.49 (-0.88), AGN: 235.96 (-1.80), JNJ: 119.32 (+0.24), GILD: 76.89 (-0.53), TSO: 74.55 (+1.24), MRK: 62.98 (+0.08), MRO: 15.49 (+0.38), CVX: 100.93 (+0.72)

Look for Shares of Celgene to Potentially Rebound after Yesterday's 1.80% Sell Off
Comtex SmarTrend(R) - Mon Aug 08, 11:54AM CDT
Celgene (NASDAQ:CELG) traded in a range yesterday that spanned from a low of $112.80 to a high of $115.53. Yesterday, the shares fell 1.8%, which took the trading range below the 3-day low of $113.86 on volume of 3.3 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
CELG: 105.49 (-0.88)

After Yesterday's Decline of 1.80%, Celgene Offers Investors Better Value
Comtex SmarTrend(R) - Mon Aug 08, 11:52AM CDT
Celgene (NASDAQ:CELG) traded in a range yesterday that spanned from a low of $112.80 to a high of $115.53. Yesterday, the shares fell 1.8%, which took the trading range below the 3-day low of $113.86 on volume of 3.3 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
CELG: 105.49 (-0.88)

Next Support Level for Celgene (CELG) is $113.72
Comtex SmarTrend(R) - Mon Aug 08, 9:21AM CDT
Celgene (NASDAQ:CELG) has opened bearishly below the pivot of $116.26 today and has reached the first level of support at $114.63. Analysts will be watching for a cross of the next downside pivot targets of $113.72 and $111.18.
CELG: 105.49 (-0.88)

BetterInvesting Magazine Releases October Stock To Study And Undervalued Stock Choices For Investors' Informational And Educational Use
PR Newswire - Fri Aug 05, 3:15PM CDT
The Editorial Advisory and Securities Review Committee of BetterInvesting Magazine today announced Celgene Corporation (NDQ: CELG) as its October 2016 "Stock to Study" and Amgen Inc. (NDQ: AMGN), as its October 2016 "Undervalued Stock" for investors' informational and educational use.
AMGN: 169.77 (-0.36), CELG: 105.49 (-0.88), CELGZ: 1.18 (+0.05)

Agios (AGIO) Q2 Loss Wider than Expected, Pipeline in Focus
Zacks Equity Research - Zacks Investment Research - Fri Aug 05, 10:10AM CDT
Agios Pharmaceuticals (AGIO) reported a wider-than-expected second-quarter 2016 loss of $1.47 per share.
GERN: 2.75 (+0.02), AGIO: 36.35 (-0.39), ANIK: 47.89 (-0.05), CELG: 105.49 (-0.88)

Juno (JUNO) Q2 Loss Wider-than-Expected, Focus on Pipeline
Arpita Dutt - Zacks Investment Research - Fri Aug 05, 6:19AM CDT
Although Juno's (JUNO) Q2 loss was wider-than-expected, investor focus primarily remains on the company's pipeline.
GERN: 2.75 (+0.02), JUNO: 28.44 (-0.85), CELG: 105.49 (-0.88), NVS: 79.38 (+1.11)

Covered Call reports for Micron, The Blackstone Group, Celgene, AIG and NetEase Inc. include trade ideas that offer returns of 20% or more!
PR Newswire - Thu Aug 04, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for AIG, BX, CELG, MU, and NTES.
MU: 16.70 (+0.06), NTES: 214.91 (-1.00), BX: 26.88 (-0.05), AIG: 59.86 (+0.45), CELG: 105.49 (-0.88)

Upgrade Alert for Celgene (CELG)
Comtex SmarTrend(R) - Thu Aug 04, 3:19AM CDT
Celgene (NASDAQ:CELG) was upgraded from Neutral to Buy at BTIG today. The stock closed yesterday at $116.14 on volume of 6.3 million shares, above average daily volume of 4.7 million. Celgene share prices have moved between a 52-week high of $140.72 and a 52-week low of $92.98 and closed yesterday at 25% above that low price at $116.14 per share. Over the last five market days, the 200-day moving average (MA) has gone down 0.6% while the 50-day MA has remained constant.
CELG: 105.49 (-0.88)

Will Agios (AGIO) Disappoint Estimates in Q2 Earnings?
Zacks Equity Research - Zacks Investment Research - Tue Aug 02, 10:23AM CDT
Agios Pharmaceuticals (AGIO), which is set to report second-quarter 2016 results on Aug 4, had posted a positive surprise of 11.59% last quarter.
ICPT: 150.74 (+3.92), AGIO: 36.35 (-0.39), EXEL: 11.54 (+0.19), CELG: 105.49 (-0.88)

Juno (JUNO) Q2 Earnings: Will the Stock Disappoint?
Arpita Dutt - Zacks Investment Research - Tue Aug 02, 5:49AM CDT
With no approved products in its portfolio, focus will remain on Juno's (JUNO) pipeline and cash burn.
RPTP: 7.28 (+0.04), TECH: 106.88 (+0.35), JUNO: 28.44 (-0.85), CELG: 105.49 (-0.88)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

2026 Prix Galien Nominations Spotlight Global Healing

Beyond the Hype: Innovating for Healthier Tomorrows Kicking off in Stockholm on December 1st, the 2026 Prix Galien Bridges Awards isn't just some schmooze-fest; it's a hard-hitting showcase of where true innovation can propel healthcare. Over at the Karolinska Institutet, the Galien Foundation is drawing powerhouses from across the Nordics+ region and showcasing...

Cell Counting Market Growth: USD 17.71 Billion by 2031

The Cell Counting Surge: Money Talks in Science You can't deny it when the numbers speak—a jump from USD 12.39 billion to USD 17.71 billion by 2031 in the cell counting market means something ain't business as usual. That's a robust 7.40% CAGR folks; it's a field being bombarded with innovation. The spark? Automated and advanced cell analysis technology taking the...

TransDigm Surges Ahead with Strong Q4 and FY Results

TransDigm's Impressive Performance in Fiscal 2026 Here's a company that's really kicking it up a notch—TransDigm Group (NYSE:TDG) just reported some solid fourth-quarter numbers that scream growth. Net sales soared to $2,988 million, marking a 23% hike from last year's fourth quarter of $2,437 million. That's a cool $551 million leap, quite the party for shareholders....

Braemar's $358 Million Refinance: A Strategic Shift

Reworking the Debt Load: Braemar's New Move Most days, when a company decides to tinker with its debt, it's like watching paint dry for investors. But with Braemar Hotels & Resorts (NYSE: BHR) announcing a $358 million refinancing package, they're bringing a fresh breath of air to the table. Lemme walk you through why this matters beyond the glossy façade of luxury hotel...

PC Richard & Son Offers Big Black Friday Savings

Holiday Prep Kicks Into High Gear As November ticks on, folks are diving headfirst into the frenzy of holiday planning and spending. What better time for a salvo of sales from P.C. Richard & Son? The appliance stalwart is throwing down the gauntlet with hefty discounts and some intriguing offers on TVs, mattresses, and more. With Black Friday looming, the savvy shopper...

Fake Profiles Dominate Daters' Trust Issues Today

Trust Erosion in the Digital Dating Arena When it comes to modern dating, we're not talking hearts and flowers anymore; it's more like an elaborate game of detective work. A recent survey from Stud or Dud highlights the harsh reality that blind trust in digital dating profiles is about as outdated as sending a singing telegram. Almost half of the respondents pinned fake...

Hi Peach Layne Rides Trend with New Hair Repair Oil

Diving into Beauty Economics with Walmart Now here's a story that ticks every box in the bargain bin playbook—Hi Peach Layne's latest move into the haircare aisle. They're launching a Hair Repair Oil loaded with claims that shout 'value!' loud enough to echo down a Walmart aisle. With a price point of $9.97, it's sliding right into Walmart's "Beauty Finds Under $10"...

Thesis Elements Expands Portfolio with Mappify Buy

Mappify Acquisition: A Smooth Move for Higher Ed Picture a college student trying to juggle classes, work, and life like it's a circus act. That's not too far off from reality, and it's where Thesis America and its new acquisition, Mappify, come into play. By scooping up Mappify, Thesis aims to untangle this scheduling chaos for students across the board. From Data to...

The DOG CATCHER: A New Spin on Pet Waste Cleanup

Revolutionizing the Dreaded Pet Waste Duty Folks, here's a little dose of innovation from the streets of Baltimore: a gadget called the DOG CATCHER. No, it’s not about catching stray dogs, but dealing with their unpleasant leavings. This invention's got a patent pending and all, promising to make the nasty business of dog waste collection a whole lot less disgusting. I...

Envista's $430M Senior Notes: A Market Move Decoded

Envista on the Move with $430M Notes Ever feel like the market's a bit like a rollercoaster with no brakes? That's kind of where we're at with Envista Holdings Corporation (NYSE: NVST) rolling out this new financial play. They just priced a hefty $430 million in Senior Notes at a solid 6.250% due 2033. In terms of the investment world, that's a pretty big splash. The...